trimethylcolchicinic acid methyl ether has been researched along with busulfan in 1 studies
*Busulfan: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. [MeSH]
*Busulfan: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bateman, JR; Stolinsky, DC; Weiner, JM | 1 |
1 other study(ies) available for trimethylcolchicinic acid methyl ether and busulfan
| Article | Year |
|---|---|
Rotational therapy with a colchicine analog in chronic granulocytic leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Colchicine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged | 1980 |